Skip to content

Study to compare two Ayurvedic nasal therapies (Kumkumadi Ghrita Nasya and Shalparni Swaras Nasya) in patients with Migraine (Ardhavbhedaka)

Comparative Clinical Evaluation Of Kumkumadi Ghrita Nasya And Shalparni Swaras Nasya In Ardhavbhedaka (Migraine) - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/094357
Enrollment
60
Registered
2025-09-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G439- Migraine, unspecified

Interventions

None listed

Sponsors

Patanjali Bhartiya Ayurvigyan Evam Anusandhan Sansthan Haridwar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with classical signs & symptoms of Ardhavabhedaka (Migraine) described as per Ayurvedic and modern science. 2. Patients between the age group of 16 years to 60 years of either sex. 3. Patients in related group who are fit for Nasya Karma / Nasya yogya vyakti.

Exclusion criteria

Exclusion criteria: 1. Patients less than 16 years and above 60 years of age. 2. Patients who are contraindicated for Nasya Karma. 3. Patients suffering from cluster headache, tension type of headache, sinus headache, and arising due to Meningitis ,Encephalitis, and Ocular manifestations. 4. Patient suffering from any systemic diseases like diabetes mellitus, heart disease, hypertension, cancer and receiving medication which may alter the results of study.

Design outcomes

Primary

MeasureTime frame
Assessment will be done on the basis of subjective parameters Intensity of Headache Frequency of headache Duration of Headache Nausea Vomiting Vertigo AuraTimepoint: Baseline (before treatment); Mid-treatment follow-up (Day 15); End of treatment (Day 21, primary time point).

Secondary

MeasureTime frame
Assessment will be done on the basis of subjective parametersTimepoint: Baseline (before treatment); Mid-treatment follow-up (Day 15); End of treatment (Day 21, primary time point).

Countries

India

Contacts

Public ContactAnanya Singh

Patanjali Ayurvigyan Evam Anusandhan Sansthan, Haridwar

agrawal.amitkumar308@gmail.com9411551545

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026